Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Change in Account Payables (2019 - 2025)

Greenwich LifeSciences filings provide 6 years of Change in Account Payables readings, the most recent being -$187590.0 for Q3 2025.

  • Quarterly Change in Account Payables rose 66.53% to -$187590.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $334127.0 through Sep 2025, down 38.56% year-over-year, with the annual reading at $921219.0 for FY2024, 2497.03% up from the prior year.
  • Change in Account Payables hit -$187590.0 in Q3 2025 for Greenwich LifeSciences, down from $248595.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $988649.0 in Q2 2024 and bottomed at -$560472.0 in Q3 2024.
  • Average Change in Account Payables over 4 years is $23474.2, with a median of -$72280.5 recorded in 2021.
  • Peak annual rise in Change in Account Payables hit 1484.8% in 2024, while the deepest fall reached 705.73% in 2024.
  • Greenwich LifeSciences' Change in Account Payables stood at -$75000.0 in 2021, then surged by 133.89% to $25415.0 in 2023, then soared by 1484.8% to $402777.0 in 2024, then tumbled by 146.57% to -$187590.0 in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Change in Account Payables are -$187590.0 (Q3 2025), $248595.0 (Q2 2025), and -$129655.0 (Q1 2025).